Status:
COMPLETED
A Study of Real-world Outcomes Among Patients Treated With Ribociclib
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Metastatic Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The main aim of the study was to evaluate the real-world tolerability and safety of ribociclib as a first-line (1L) treatment among adults with hormone receptor-positive/human epidermal growth factor ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosed with mBC on or after 1 January 2015.
- Had HR+/HER2- test results.
- Received ribociclib and endocrine therapy in 1L treatment.
- Patients had a gap of 90 days or less between mBC diagnosis date and the first structured EHR activity (e.g., lab tests and prescriptions) after metastatic diagnosis date.
- Exclusion criteria:
- None identified.
Exclusion
Key Trial Info
Start Date :
April 24 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 7 2024
Estimated Enrollment :
373 Patients enrolled
Trial Details
Trial ID
NCT07148505
Start Date
April 24 2024
End Date
November 7 2024
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936